- IN₹502.06bn
- IN₹470.57bn
- IN₹64.31bn
Indian pharma stocks fall after Trump's new drug tariffs
Brief: Gland Pharma Gets USFDA Approval For Vasopressin In 5% Dextrose RTU Injection
Brief: Gland Pharma Receives Approval From USFDA For Norepinephrine Bitartrate In 5% Dextrose Injection
Brief: Gland Pharma Receives USFDA Approval For Cangrelor Injection
India's Gland Pharma gains on upbeat quarterly results
India's Gland Pharma posts quarterly profit rise on Cenexi recovery, Europe sales growth
Brief: Gland Pharma Q1 Consol Net Profit 2.15 Billion Rupees IBES EST. 2.03 Billion Rupees
ET
Brief: Gland Pharma Receives GMP Compliance Certificate From Danish Agency
Brief: Gland Pharma Gets EIR From U.S. FDA For Company’S JNPC Facility, Visakhapatnam
Brief: Gland Pharma Says ANSM Issues Final Report With 11 Observations Cenexi's Facility
India's Gland Pharma rises on US FDA nod for blood pressure drug
Brief: Gland Pharma Receives Approval For Angiotensin II Acetate Injection
Indian pharma stocks gain after US order exempts generic drugs from price cuts
India's Gland Pharma posts quarterly profit fall, hit by sluggish U.S. sales
Brief: Gland Pharma Q4 Consol Net Profit 1.87 Billion Rupees
Indian pharma stocks decline after Trump again threatens tariffs (updated)
Indian drugmakers fall after Trump signals 'major' pharma tariffs
Indian pharma stocks decline after Trump again threatens tariffs